Maridebart cafraglutide: indexed trial records
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
This page carries 5 of the 13 records the literature query returned for Maridebart cafraglutide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index.
Every row below resolves to a real identifier and names the study model the indexer assigned. The record class is read from the publication type on the record itself. Nothing here states what a record found.
At a glance
- Class
- Incretin receptor agonists
- Receptor targets as recorded
- GLP-1 receptor, GIP receptor
- Records indexed here
- 5
- Records returned by the query
- 13
- Publication years covered
- 2024–2026
- Query retrieved
- 2026-10-12
Shape of the indexed record set
| Record class | Records |
|---|---|
| Phase 2 | 1 |
| Phase 1 | 1 |
| Review or synthesis | 2 |
| Not a registered trial record | 1 |
| Study model as assigned | Records |
|---|---|
| human trial | 2 |
| other | 2 |
| rodent | 1 |
Study model is the indexer’s own assignment, taken from the MeSH population headings and the publication type. It is not a judgement about how well a record was conducted.
Endpoint coverage
| Endpoint | Records for this compound | Records across all compounds in scope |
|---|---|---|
| Body weight and adiposity | 5 | 108 |
| Glycaemic control | 3 | 117 |
| Cardiovascular | 0 | 30 |
| Renal | 0 | 10 |
| Hepatic | 1 | 9 |
| Neurological | 0 | 18 |
Derived record-set tier
Preparation or mixture
(INFERRED, derived from record counts)
Basis: PubChem returned no compound record for this name, so the subject is a preparation, protein or mixture rather than a defined small molecule; identity fields are unsourced.
This label counts record types. It is not an assessment of clinical efficacy, of safety, of
study quality or of consensus, and it does not rank one compound above another.
What the corpus does not carry for this compound
- Identity fields with no source retrieved: cas, pubchem_cid, uniprot_id, molecular_formula, molecular_weight, sequence.
- Reported half-life: no source retrieved, so the value reads Unknown.
- Amounts reported in the cited literature: no row recorded.
- Adverse effects reported in the cited literature: no row recorded.
- Long-form mechanism: not written, because no source was read in full.
- Records the query returned that this corpus does not carry: 8.
An absent row records the absence of a retrieved report, never the absence of the thing itself.
Application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[1]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
The records
Phase 2 — 1 record
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 4 | pmid:40549887 | 2025 | Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial The New England journal of medicine · Clinical Trial, Phase II, Multicenter Study | human trial | Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Receptors, Gastrointestinal Hormone; Anti-Obesity Agents; Immunoconjugates; Body Mass Index |
Phase 1 — 1 record
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 5 | pmid:38316982 | 2024 | A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings Nature metabolism · research-article, Clinical Trial, Phase I | human trial | Animals; Humans; Mice; Obesity; Weight Loss; Peptides; Male; Glucagon-Like Peptide 1 |
Review or synthesis — 2 records
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 1 | pmid:41054801 | 2026 | Novel GLP-1-based Medications for Type 2 Diabetes and Obesity Endocrine reviews · Review | other | Animals; Humans; Diabetes Mellitus, Type 2; Obesity; Hypoglycemic Agents; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucagon-Like Peptide-1 Receptor Agonists |
| 3 | pmid:42166683 | 2026 | The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms Annual review of nutrition · Review | other | Animals; Humans; Obesity; Gastric Inhibitory Polypeptide; Receptors, Gastrointestinal Hormone; Anti-Obesity Agents; Drug Therapy, Combination; Glucagon-Like Peptide 1 |
Not a registered trial record — 1 record
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 2 | pmid:41287212 | 2026 | A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice Diabetes, obesity & metabolism · Comparative Study, research-article | rodent | Liver; Adipose Tissue; Animals; Mice, Inbred C57BL; Mice; Insulin Resistance; Obesity; Body Weight |
Where this page sits
Receptor targets
- GLP-1 receptor: every compound in scope acting at it
- GIP receptor: every compound in scope acting at it
All compounds in scope: the trial index. Coverage by endpoint: the endpoint index.
Review status
- Review tier
- High impact
- State
- Pending qualified review
- Compiled by
- automated pipeline
- Qualified clinical review
- None on record
Why this tier was assigned
- 2 indexed record(s) are interventional human trials
- the class covers weight-management and metabolic prescribing, the highest-risk consumer subject in this corpus
Checks the pipeline performed
- every cited source id resolves to a sources[] row on the entity
- every identifier is a well-formed PMID or DOI
- study model derived only from assigned MeSH headings and publication types
- banned-phrase lint over rendered HTML including title, meta, alt and JSON-LD
- unknown values render as the literal word Unknown
Checks the pipeline did not perform
- no full text was read
- no clinical appraisal of any study
- no assessment of whether the indexed set is representative of the literature
A high_impact profile with qualified_review null must not be published as indexable. Compilation and linting are not clinical validation.
Sources
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:maritide
- Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity. Journal of medicinal chemistry (2026). pmid:41941715
- Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications. Antibody therapeutics (2026). pmid:42592044
- Phase I results for AMG 133. Nature reviews. Endocrinology (2024). pmid:38388678
- Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. The New England journal of medicine (2025). pmid:40549887
- Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. The New England journal of medicine (2025). pmid:41337722
- Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply. The New England journal of medicine (2025). pmid:41337724